Here are three points:
1. Mr. Shin comes to Syapse from The Advisory Board, where he was senior vice president of national and strategic accounts.
2. He spent 22 years working at The Advisory Board.
3. In his new role, Mr. Shin will help grow Syapse through building and expanding its partnerships in the precision medicine arena.
More articles on precision medicine:
Nature retracts controversial 2017 study on potential CRISPR gene-editing errors
Philips to lead BigMedilytics consortium to improve medical outcomes with big data
Up to 40% of positive results in direct-to-consumer genetic tests are wrong, study suggests
